Viva biotech announces its 2025 interim results: cro revenue returned to positive growth, new cdmo commercialization projects showed promising growth

Results highlights for interim results ended 30 june 2025 revenue reached rmb831.9 million gross profit amounted to rmb339.4 million gross profit margin was 40.8%, an increase of 6.3 percentage point net profit amounted to rmb148.6 million, increased by 3.1% yoy adjusted non-ifrs net profit reached rmb183.5 million, increased by 9.1% yoy shanghai , aug. 28, 2025 /prnewswire/ -- on august 28, 2025, viva biotech holdings group ("viva biotech", "the group" or "the company", stock code: 1873.hk) announced that the group's revenue amounted to rmb831.9 million, and the group's gross profit of rmb339.4 million. the group's gross profit margin was 40.8%, an increase of 6.3 percentage points from the corresponding period of last year, primarily attributable to the optimization and adjustment of langhua's business structure, improved operational efficiency in cro business, and contributions from new business segments.
CDMO Ratings Summary
CDMO Quant Ranking